Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 495-503 , May 2006

Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors

  • Elisa García-Garayoa

      Affiliations

    • Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH-5232 Villigen PSI, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 56 310 28 17; fax: +41 56 31 0 28 49.
    • ,
  • Veronique Maes

      Affiliations

    • Vrije Universiteit Brussel, Department of Organic Chemistry, B-1050 Brussel, Belgium
    • ,
  • Peter Bläuenstein

      Affiliations

    • Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH-5232 Villigen PSI, Switzerland
    • ,
  • Alain Blanc

      Affiliations

    • Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH-5232 Villigen PSI, Switzerland
    • ,
  • Alexander Hohn

      Affiliations

    • Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH-5232 Villigen PSI, Switzerland
    • ,
  • Dirk Tourwé

      Affiliations

    • Vrije Universiteit Brussel, Department of Organic Chemistry, B-1050 Brussel, Belgium
    • ,
  • P. August Schubiger

      Affiliations

    • Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH-5232 Villigen PSI, Switzerland

Received 15 November 2005 ,Revised 10 January 2006 ,Accepted 12 January 2006.

References 

  1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin. 2000;50:7–33
  2. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?. Ann Surg. 1995;221:59–66
  3. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survival. Ann Surg. 1996;223:273–279
  4. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–282
  5. Anderson CJ, Dehdashti F, Cutler D, Schwarz SW, Laforest R, Bass LA, et al. 64Cu-TETA-Octreotide as PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213–221
  6. Nemeroff CB, Luttinger D, Prange AJJ. Neurotensin: central nervous system effects of a neuropeptide. Trends Neurosci. 1980;3:212–215
  7. Vincent P. Neurotensin receptors: binding properties, transduction pathways and structure. Cell Mol Neurobiol. 1995;15:501–512
  8. Kitabgi P. Effects of neurotensin on intestinal smooth muscle: application to the study of structure-activity relationships. Ann N Y Acad Sci. 1982;400:37–44
  9. Labbé-Jullié C, Dubuc I, Brouard A, Doulut S, Bourdel E, Pelaprat D, et al. In vivo and in vitro structure–activity studies with peptide and pseudopeptide neurotensin analogues suggest the existence of distinct central neurotensin receptor subtypes. J Pharmacol Exp Ther. 1994;268:328–336
  10. Tyler BM, Cusack B, Douglas CL, Souder T, Richelson E. Evidence for additional neurotensin receptor subtypes: neurotensin analogues that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Res. 1998;792:246–252
  11. Vincent JP, Mazella P, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20:302–309
  12. Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, Tommerup N, Rasmussen HH, et al. Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J Biol Chem. 1997;272:3599–3605
  13. Mazella J, Zsurger N, Navarro V, Chabry J, Kaghad M, Caput D, et al. The 100-kDa neurotensin receptor is gp95/sortilin a non G-protein-coupled receptor. J Biol Chem. 1998;792:26273–26276
  14. Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM. Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipasa. J Biol Chem. 1999;27:8832–8836
  15. Petersen CM, Nielsen MS, Jacobsen C, Tauris J, Jacobsen L, Gliemann J, et al. Propeptide cleavage conditions sortilin/neurotensin receptor-3 ligand binding. EMBO J. 1999;18:595–604
  16. Reubi JC, Waser B, Friess H, Büchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998;42:546–550
  17. Ehlers RA, Kim S, Zhang Y, Ethridge RT, Murrilo C, Hellmich MR, et al. Gut peptide receptor expression in human pancreatic cancers. Ann Surg. 2000;231:838–848
  18. Kitabgi P, De Nadai F, Rovère C, Bidard JN. Biosynthesis, maturation, release and degradation of neurotensin and neuromedin N. Ann N Y Acad Sci. 1992;668:30–42
  19. Davis TP, Konings PNM. Peptidases in the CNS: formation of biologically active, receptor-specific peptide fragments. Crit Rev Neurobiol. 1993;7:163–174
  20. Garcia-Garayoa E, Blaeuenstein P, Bruehlmeier M, Blanc A, Iterbeke K, Conrath P, et al. Preclinical evaluation of a new, stabilized neurotensin(8–13) pseudopeptide radiolabeled with 99mTc. J Nucl Med. 2002;43:374–383
  21. Bruehlmeier M, Garcia Garayoa E, Blanc A, Holzer B, Geergely S, Touwé D, et al. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. Nucl Med Biol. 2002;29:321–327
  22. Buchegger F, Bonvin F, Kosinski M, Schaffland A, Prior J, Reubi JC, et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med. 2003;44:1649–1654
  23. Wester H-J, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging. 2002;29:28–38
  24. Schottelius M, Wester H-J, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr3-Octreotide by conjugation with carbohydrates. Bioconj Chem. 2002;13:1021–1030
  25. Maes V, García-Garayoa E, Bläuenstein P, Tourwé D. Novel 99mTc-labelled neurotensin analogs with optimized biodistribution properties. J Med Chem [in press].
  26. Schibli R, La Bella R, Alberto R, Garcia Garayoa E, Ortner K, Abram U, et al. Influence of the denticity of ligand systems on the in vitro and in vivo behavior of 99mTc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconj Chem. 2000;11:345–351
  27. García-Garayoa E, Allemann-Tannahill L, Bläuenstein P, Willmann M, Carrel-Rémy N, Tourwé D, et al. In vitro and in vivo evaluation of new radiolabeled neurotensin(8–13) analogues with high affinity for NT1 receptors. Nucl Med Biol. 2001;28:75–84
  28. Bauer R, Pabst H-W. Tc-generators. Yield of 99mTc and ratio to inactive 99Tc. Eur J Nucl Med. 1982;7:35–36
  29. Hermans E, Octave JN, Maloteaux JM. Receptor mediated internalization of neurotensin in transfected Chinese hamster ovary cells. Biochem Pharmacol. 1994;47:89–91
  30. Mazella JE, Leonard K, Chabry J, Kitabgi P, Vincent JO, Beaudet A. Binding and internalization of iodinated neurotensin in neuronal cultures from embryonic mouse brain. Brain Res. 1991;564:249–255
  31. Chabry J, Gaudriault G, Vincent JP, Mazella J. Implications of various forms of neurotensin receptors in the mechanism of internalization of neurotensin in cerebral neurons. J Biol Chem. 1993;268:17138–17144
  32. Faure MP, Labbé-Jullié C, Cashman N, Kitabgi P, Beaudet A. Binding and internalization of neurotensin in hybrid cells derived from septal cholinergic neurons. Synapse. 1995;20:106–116
  33. de Visser M, Janssen PJJM, Srinivasan A, Reubi JC, Waser B, Erion JL, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134–1139
  34. Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J Med Chem. 2003;46:3403–3411
  35. Tanaka K, Masu M, Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron. 1990;4:847–854
  36. Mule F, Serio R, Postorino A, Vetri T, Bonvissuto F. Antagonism by SR-48692 of mechanical responses to neurotensin in rat intestine. Br J Pharmacol. 1996;117:488–492

☆ Work partly funded by the Fund for Scientific Research-Flanders (Belgium), contract No. G.0036.04.

PII: S0969-8051(06)00012-6

doi: 10.1016/j.nucmedbio.2006.01.007

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 495-503 , May 2006

Article Tools

* Image Usage & Resolution